Yahoo Search Búsqueda en la Web

Entrar

Resultado de búsqueda

  1. pro.aace.com › pdfs › diabetesAMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AMERICAN ...

    PROFILES OF ANTIDIABETIC MEDICATIONS SU Mild Few adverse events or possible benefits Use with caution Likelihood of adverse effects GLN Moderate/ Severe CARDIAC 1. Liraglutide—FDA approved for prevention of MACE events. 2. Empagliflozin—FDA approved to reduce CV mortality. Canagliflozin—FDA approved to reduce MACE events. 3.

    • 4MB
    • 10

  2. pro.aace.com › pdfs › diabetesAACE COMPREHENSIVE TYPE 2 DIABETES 2 0

    1 Order of medications represents a suggested hierarchy of usage; length of line reflects strength of recommendation 2 If not at goal in 3 months, proceed to next level therapy *CKD 3: canagliflozin; HFrEF: dapagliflozin

    • 4MB
    • 10

  3. www.ncbi.nlm.nih.gov › pmc › articlesClinical Review of Antidiabetic Drugs: Implications for Type ...

    24 de ene. de 2017 · The major classes of oral antidiabetic medications include biguanides, sulfonylureas, meglitinide, thiazolidinedione (TZD), dipeptidyl peptidase 4 (DPP-4) inhibitors, sodium-glucose cotransporter (SGLT2) inhibitors, and α-glucosidase inhibitors.

    • Arun Chaudhury, Chitharanjan Duvoor, Vijaya Sena Reddy Dendi, Shashank Kraleti, Aditya Chada, Rahul ...
    • 10.3389/fendo.2017.00006
    • 2017
    • Front Endocrinol (Lausanne). 2017; 8: 6.

  4. www.diabetesed.net › page › _filesAACE COMPREHENSIVE DIABETES MANAGEMENT ALGORITHM 2013

    Complications-Centri c Model for Care of the Overweight/Obese Patient Prediabetes Algorithm Goals of Glycemic Control Algorithm for Adding/Intensifying Insulin CVD Risk Factor Modifications Algorithm Profiles of Antidiabetic Medications Principles for Treatment of Type 2 Diabetes.

  5. www.ncbi.nlm.nih.gov › pmc › articlesTrends in Antidiabetic Drug Discovery: FDA Approved Drugs ...

    19 de ene. de 2022 · To provide an up-to-date account of the current trends of antidiabetic pharmaceuticals, this review offers a comprehensive analysis of the main classes of antihyperglycemic compounds and their mechanisms: insulin types, biguanides, sulfonylureas, meglitinides (glinides), alpha-glucosidase inhibitors (AGIs), thiazolidinediones (TZD ...

    • 10.3389/fphar.2021.807548
    • 2021
    • Front Pharmacol. 2021; 12: 807548.

  6. www.sciencedirect.com › science › articleCurrent Antidiabetic Drugs: Review of Their Efficacy and Safety

    1 de ene. de 2018 · This review will provide an overview of the currently availability antidiabetic agents. Among the available antihyperglycemic agents, the dipeptidyl peptidase-4 inhibitors are efficacious alone and in combination with other agents, and have low side effects compared with metformin.

  7. www.frontiersin.org › journals › endocrinologyFrontiers | Clinical Review of Antidiabetic Drugs ...

    23 de ene. de 2017 · The major classes of oral antidiabetic medications include biguanides, sulfonylureas, meglitinide, thiazolidinedione (TZD), dipeptidyl peptidase 4 (DPP-4) inhibitors, sodium-glucose cotransporter (SGLT2) inhibitors, and α-glucosidase inhibitors.